A satellite symposium in conjunction with Oncology Pharmacists Connect 2023.
If you would like to attend in person, please visit our Oncology Pharmacists Connect 2023 registration page: www.pharmacytimes.org/Connect2023
Program Description
Myelofibrosis (MF) is a myeloproliferative neoplasm with a plethora of systemic symptoms that may progress to leukemia. Currently, the only cure is allogeneic hematopoietic stem cell transplantation (HSCT), but many patients are ineligible for HSCT. First-line treatment most frequently incorporates Janus-associated kinase inhibitors, but the use of these agents is limited due to development of resistance and associated serious adverse events. With several novel agents under investigation for MF, a better understanding of potential new therapies is essential to modifying the natural disease course of MF and slow disease progression. Pharmacists on the oncology care team have important roles in education and supportive care of patients with MF to help improve adherence and reduce toxicity. This program will explore treatment goals, emerging therapies, and updated recommendations for treatment selection and sequencing in patients with MF. Additionally, expert faculty will review patient case examples to discuss and debate real-world treatment and management scenarios in patients with MF.
Target audience: Health-system pharmacists, managed care pharmacists, oncology pharmacists, and specialty pharmacists
Type of activity: Application
Release date: June 17, 2023
Expiration date: August 17, 2023
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the latest guidelines and clinical recommendations for the management of myelofibrosis (MF)
- Analyze the emerging utility of novel agents in treating MF
- Develop strategies to optimize care for patients receiving targeted treatment for MF including patient education, supportive care, and toxicity management
James A. Davis, PharmD, BCOP
Clinical Pharmacy Specialist – Malignant Hematology
The Medical University of South Carolina (MUSC) Hollings Cancer Center
Assistant Professor
MUSC College of Pharmacy
Charleston, South Carolina
Shawn Griffin, PharmD, BCOP
Clinical Assistant Professor - Department of Clinical Pharmacy Practice
University of California, Irvine
Irvine, California
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-243-L01-P. The activity is available for CE credit through August 17, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
James A. Davis, PharmD, BCOP
Shawn Griffin, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Amy L. Morris, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information: